Open AccessControl of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
Author(s) -
Kwok Wang Chun,
Tam Terence Chi Chun,
Lui Macy Mei Sze,
Lam David Chi Leung,
Ho James Chung Man
Publication year - 2017
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.224
Subject(s) - alectinib , ceritinib , anaplastic lymphoma kinase , crizotinib , medicine , lung cancer , brain metastasis , adenocarcinoma , oncology , alk inhibitor , cancer , pathology , metastasis , malignant pleural effusion
Brain metastasis from non‐small cell lung cancer remains a challenge to physicians. It occurs in 30% of patients with advanced stage adenocarcinoma of lung and is often regarded as the ominous sign of disease progression and death. Alectinib is likely to be a promising agent, even after the failure of crizotinib and ceritinib, for patients with anaplastic lymphoma kinase ( ALK ) ‐driven non‐small cell lung cancer with brain metastasis, resulting in a durable response for both intracranial and extra‐cranial diseases.